Replies to post #249426 on Biotech Values

[RNsidersbuying]

NKTX 9.87 - the April19-$10-Call Option is currently bidding at $1.10. Their recent K filing showed $5+ cash remaining and they just secondaried at $10 which should put them well above $5+ cash per share accompanied by some upcoming inevitable touting...one can only hope the option premiums remain this high?

https://finance.yahoo.com/news/nkarta-announces-pricing-240-million-103000060.html

New and existing investors participated in the offering, including Adage Capital Partners LP, Boxer Capital, Commodore Capital, Cormorant Asset Management, an affiliate of Deerfield Management, EcoR1 Capital, Janus Henderson Investors, OrbiMed, RA Capital Management, Ridgeback Capital Investments, Samsara BioCapital, SR One, and a leading mutual fund.